A composition comprising a hydrogen peroxide source and at least one salicylate. Preferably, the hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide.

The present invention relates to a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (a dual-linker) containing a 2,3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

The present invention relates to methods of co-administration of various vitamins and mineral compositions, and in a specific embodiment, said methods comprise co-administering one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D.sub.3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states; and kits provided for co-administration of various vitamin and mineral compositions, and in a specific embodiment, said kits comprise one composition comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D.sub.3, vitamin E, iron, magnesium and zinc, and a second composition comprising omega-3 fatty acids, such as DHA, to supplement the nutritional needs of individuals within physiologically stressful states.

Described herein are oral delivery systems for use in delivering live mammalian cells to the intestinal tract of an individual.

Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.

##STR00001##

This invention refers to a probiotic composition consisting of the bacteria Lactobacillus rhamnosus, Lactobacillus casei and Bifidobacterium longum, preferably of the strains L. rhamnosus CECT8361, L. casei CECT9104 and B. longum CECT7347, and its use as an antioxidant. This composition is particularly useful in the treatment and/or prevention of damage, at the molecular level, caused by oxidative stress, preferably during high intensity physical exercise.

In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.

This disclosure relates to anti-coronavirus (e.g., SARS-CoV-2) antibodies or antigen-binding fragments and uses thereof.

The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.